The German Government has invested €300m in mRNA-focused CureVac. The investment is made through Kreditanstalt für Wiederaufbau (KfW) and is supported by investor Dietmar Hopp, a major shareholder in CureVac.

The money will be used to advance CureVac’s mRNA platform and pipeline, which includes a Covid-19 vaccine candidate. In mid-May the German company announced positive pre-clinical results for its Covid-19 vaccine; it plans to initiate a Phase I/IIA trial in June.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Federal Minister for Economic Affairs and Energy Peter Altmaier noted:  “The German Federal Government has decided to invest in this promising company because it expects that this will accelerate the development programs and provide the means for CureVac to harness the full potential of its technology.

This is also of high importance for industrial policy as we in Germany and Europe need these essential research results and technologies.

“At the same time, today’s move is a first and important implementation of the comprehensive Corona Economic Stimulus and Future Technologies Package, which was agreed on by the Federal Government on 3 June 2020. With this package, we aim to secure more independence in the entire production process of medical substances and vaccines.”

CureVac emphasised that this investment does not mean the German Government has exclusive rights to the vaccine: “Of course, we will supply the Federal Republic of Germany with our vaccine when it is fully developed. In general, however, our goal is to help as many people worldwide as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.